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Previewsphysicochemical characteristics, it seems
likely that freely circulating small oligo-
mers may be better seeds; however,
larger polymers may be more stable
against biological clearance.
(4) What are the molecular bases for the
selective cellular accumulation of NFTs?
Even though spreading of tau pathology
may provide a feasible explanation for
the mechanism by which deposition of
tau aggregates progresses in the brain
of AD patients, this phenomenon does
not explain why only some of the intercon-
nected neurons develop NFTs. The
reason behind the selective accumulation
of different types of misfolded aggregates
in distinct brain regions is a major
unknown in the field. Possible explana-
tions for this intriguing phenomenon could
be the involvement of cellular receptors,
the differential functioning of clearance
mechanisms, or the distinct level of
expression of the proteins involved in
misfolding.
The finding that tau pathology spreads
in the brain by a prion-like mechanism
not only helps us understand the processinvolved in disease pathogenesis and
provides a feasible explanation for the
stereotypical progression of these lesions
in AD brain but may also lead to the iden-
tification of new targets for therapeutic
intervention. Indeed, preventing the initial
formation of seeds or the subsequent
spreading of tau aggregates may repre-
sent interesting strategies for a much-
needed treatment for AD and related
tauopathies.REFERENCES
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In this issue of Neuron, Napoli et al. (2012) demonstrate that elevated ERK/MAPK signaling in Schwann cells
is a crucial trigger for Schwann cell dedifferentiation in vivo. Moreover, the authors show that dedifferentiated
Schwann cells have the potential to coordinate much of the peripheral nerve response to injury.A remarkable feature of the peripheral
nerve is the ability to regenerate after
injury. Regeneration is associated with
an extraordinary series of changes in
Schwann cells (reviewed in Chen et al.,
2007). After injury, Schwann cells dedif-
ferentiate into a progenitor-like state,
proliferate, and repopulate the damaged
nerve. In the nerve segment distal to the
site of injury, columns of dedifferentiatedSchwann cells form the Bands of Bungner
and provide an important substrate for
regenerating axons. Once axons have
regenerated, Schwann cells then redif-
ferentiate and remyelinate. Numerous
axonal-, Schwann cell-, and immune-
derived mediators are thought to be
required for the regenerative response.
Given the complex morphological
changes and the number of mediatorspotentially involved, it would seem un-
likely that the Schwann cell’s multifaceted
response to injury could be regulated by
a single pathway.
Indeed, within hours of nerve injury,
increased activity in multiple pathways
including ERK/MAPK, JNK/c-Jun, Notch,
and JAK-STAT can be detected in
Schwann cells (Sheu et al., 2000; Wood-
hoo et al., 2009). In vivo studies haveFebruary 23, 2012 ª2012 Elsevier Inc. 623
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Previewsclearly shown that loss of Notch hinders
Schwann cell dedifferentiation after
injury, whereas virally mediated activa-
tion of Notch in intact nerves drives
Schwann cell dedifferentiation (Woodhoo
et al., 2009). Further, Schwann cell dedif-
ferentiation is inhibited in c-Jun mutant
mice, fitting with the overall role of JNK
signaling in response to stress and its
role in mediating Wallerian degeneration
(Parkinson et al., 2008). A key effect of
Notch and c-Jun is to inhibit the effects
of promyelinating transcription factors,
such as Egr2 (reviewed in Pereira et al.,
2012).
Despite the importance of JNK/c-Jun
and Notch, the elevation and extent of
ERK/MAPK activation is apparently more
pronounced than that of JNK after nerve
transection (Sheu et al., 2000). Indeed
after peripheral nerve injury, phosphory-
lated ERK/MAPK levels in the distal nerve
increase >3-fold and are maintained at
heightened levels in the Bands of Bungner
for up to a month. In previous work, Lloyd
and colleagues examined the role of
ERK/MAPK activation in vitro by trans-
fecting DRG neuron/Schwann cell cocul-
tures with a tamoxifen (TMX)-responsive,
constitutively active Raf construct
(Raf-ER) (Harrisingh et al., 2004). TMX
administration to these cultures resulted
in increased ERK/MAPK phosphorylation,
myelin breakdown, and Schwann cell
dedifferentiation in vitro (Harrisingh et al.,
2004). However, another group has
shown that Schwann cell monocultures
do not require ERK/MAPK for many
aspects of dedifferentiation induced by
the withdrawal of cAMP (Monje et al.,
2010). An assessment of the importance
of ERK/MAPK for Schwann cell dediffer-
entiation in vivo is clearly important and
might resolve the disparate conclusions
arising from in vitro analyses.
In this issue of Neuron, Napoli et al.
(2012) have elegantly tested the function
of Raf/MEK/ERK signaling in Schwann
cell dedifferentiation in vivo. The authors
generated a novel transgenic mouse
model that allows for Schwann cell-
specific, reversible activation of ERK/
MAPK by placing Raf-ER under the con-
trol of a modified myelinating Schwann
cell-specific promoter, P0 (P0-Raf-ER
mice). Injection of TMX into P0-Raf-ER
mice induced a robust increase in phos-
phorylated-ERK/MAPK levels in Schwann624 Neuron 73, February 23, 2012 ª2012 Elscells within 24 hr, comparable to that seen
in the distal segment after nerve injury.
With a protocol of five consecutive daily
injections of TMX, increased ERK/MAPK
activity was maintained for a total period
of 2 weeks.
Strikingly, 3 days of elevated ERK/
MAPK activation clearly stimulated
Schwann cell dedifferentiation in vivo
(Figure 1). The authors show a rapid
decrease in the expression of myelin
genes, P0, MBP, and periaxin, and an
increase in the expression of Schwann
cell progenitor genes, Krox24, p75, and
cyclinD1. Further, a significant increase
in the number of proliferating p75-
expressing Schwann cell progenitors in
the nerve was observed. By day 10, overt
demyelination in the nerve and motor/
proprioceptive deficits on behavioral
testing were apparent. Importantly, ob-
vious axonal damage was not observed
at any time point analyzed. Thus, activa-
tion of a single pathway, RAF/MEK/ERK,
is sufficient for the induction of Schwann
cell dedifferentiation in vivo, even in a
nerve that lacks damaged axons. The
result is all the more remarkable in
that there was no requirement for direct
activation of the JNK andNotch pathways
previously implicated as required for the
dedifferentiation response.
Importantly, remyelination and motor
recovery became apparent in P0-Raf-ER
mice a few weeks after ERK/MAPK
activity returned to basal levels. A pro-
longed regimen of TMX injections led to
a corresponding delay in motor recovery.
These data show that the dedifferentiated
state can be maintained as long as
ERK/MAPK levels remain high. Further,
remyelination may depend upon a sub-
sequent decrease in ERK/MAPK activity.
The authors then asked whether ERK/
MAPK signaling was required for the
Schwann cell dedifferentiation that nor-
mally occurs in injured sciatic nerves.
Administration of a pharmacological
MEK1/2 inhibitor, PD0325901, immedi-
ately before nerve injury strongly inhibited
the proliferation changes associated
with Schwann cell dedifferentiation. The
gene expression changes associated
with dedifferentiation were inhibited by
PD0325901, but only partially. Due to the
side effects of the pharmacological
approach, the period of analysis was
restricted to 2–3 days after injury, andevier Inc.the dose of inhibitor did not completely
block ERK/MAPK activation. This result
is consistent with the group’s previous
in vitro report (Harrisingh et al., 2004),
fits with predictions from the P0-Raf-ER
model, and supports the view that injury-
induced ERK/MAPK signaling is required
for Schwann cell dedifferentiation in vivo.
However, given the issues with the phar-
macological experiments, testing the
requirement for ERK/MAPK in Schwann
cell dedifferentiation using a conditional
knockout approach should be an impor-
tant future goal.
The P0-Raf-ER model provided a
unique opportunity for the authors to test
whether dedifferentiated Schwann cells
are sufficient to activate other cellular
responses to nerve injury. The recruitment
of immune cells is particularly important
for clearing axon and myelin debris and
promoting subsequent revascularization
in injured nerves (reviewed in Benowitz
and Popovich, 2011). However, it is not
clear whether debris, axons, or dediffer-
entiated Schwann cells provide the cues
to initiate the inflammatory response.
Napoli et al. therefore examined the
inflammatory reaction in the sciatic nerve
of P0-Raf-ER mice. Remarkably, a clear
infiltration of T cells, macrophages,
neutrophils, and mast cells was observed
within 3 to 5 days of TMX injection
(Figure 1). Moreover, in injured nerves,
PD0325901 administration blocked the
recruitment of immune cells. Fibroblasts
did not appear to undergo any of the
changes typically associated with nerve
injury. The fibroblast response may
require overt tissue damage and pre-
sumably depends upon cues that are not
Schwann cell derived. Conditioned
media from Raf-ER-expressing Schwann
cells was also able to recruit immune
cells, but not fibroblasts, in vitro. These
data demonstrate that dedifferentiated
Schwann cells are capable of initiating
a complete immune reaction in a normal
peripheral nerve.
What are the Schwann cell-derived
inflammatory molecules that are in-
creased following dedifferentiation? To
identify candidates, a previously reported
microarray analysis of cultured Raf-ER-
expressing Schwann cells was reana-
lyzed (Parrinello et al., 2008). A number
of relevant secreted cues were regulated,
including c-kit, MCP-1, IL11, Cxcl10,
Figure 1. Elevated ERK/MAPK Activation in Myelinating Schwann Cells Is Sufficient to Induce Schwann Cell Dedifferentiation and the
Recruitment of Immune Cells to the Peripheral Nerve
On day 0, P0-Raf-ERmice began a regimen of five daily consecutive injections of tamoxifen (TMX) to trigger elevations in phosphorylated ERK/MAPK levels. TMX
reversibly activates a constitutively active Raf-ER fusion protein expressed only in myelinating Schwann cells. On day 3, ERK/MAPK activation resulted in
changes in gene expression, indicative of Schwann cell dedifferentiation into a progenitor-like state. Further, blood-nerve-barrier breakdown and the recruitment
of immune cell types was observed, possibly due to the upregulation of candidate secreted factors by dedifferentiating Schwann cells. At day 10, overt demy-
elination is apparent. Dedifferentiated Schwann cells and immune cells are present throughout the nerve. Remarkably, no axonal damage is observed. By day 90,
after phosphorylated ERK/MAPK levels returned to basal levels, the blood-nerve barrier was restored, and dedifferentiated Schwann cells redifferentiate and
remyelinate. However, myelination is more heterogeneous in recovered nerves.
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PreviewsScye1, TGFb, GDNF, VEGF, FGF2,
Jagged1, and Areg. The upregulation of
some candidates was confirmed in vivo
by performing qRT-PCR on sciatic nerves
samples from P0-Raf-ER mice. Further,
an increase in the levels of MCP-1,
VEGF, TIMP-1, and PDGF was detected
in conditioned media from Raf-ER-
expressing Schwann cell cultures. It will
be interesting in the future to test the
precise role of these candidate molecules
in the early stages of the injury response.It is important to place these results
in the context of other studies on regu-
lation of Schwann properties by ERK/
MAPK signaling. Interestingly, conditional
deletion of ERK/MAPK or Shp2, an
upstream ERK/MAPK activator, in embry-
onic Schwann cell progenitors prevents
Schwann cell differentiation and myelina-
tion in vivo (Grossmann et al., 2009;
Newbern et al., 2011). Thus, there is
a requirement for ERK/MAPK signaling
both for differentiation of SchwannNeuron 73,cell precursors and dedifferentiation of
mature Schwann cells. What explains
this seemingly paradoxical requirement
for ERK/MAPK in Schwann cell differ-
entiation during development and
dedifferentiation following injury? The
authors suggest that distinct levels of
ERK/MAPK activity define the state of
Schwann cell differentiation; basal levels
are necessary for differentiation of pre-
cursors while high ERK/MAPK activity
drives dedifferentiation and proliferation.February 23, 2012 ª2012 Elsevier Inc. 625
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the concentration-dependent effects of
neuregulin-1 on Schwann cells, in which
low levels drive myelination and high
levels drive dedifferentiation (Syed et al.,
2010).
Another possibility is that ERK/MAPK
may interact with other pathways that
regulate Schwann cell fate changes.
In vitro experiments have shown that
cAMP/PKA signaling modulates the
Schwann cell response to NRG1 (Arthur-
Farraj et al., 2011; Monje et al., 2010). In
an extension of this model, heightened
cAMP/PKA signaling in developing nerves
directs ERK/MAPK signaling toward
differentiation. In injured adult nerves,
cAMP levels are diminished, which links
ERK/MAPK to dedifferentiation. Deter-
mining how these signaling pathways
control changes in the transcriptional
network that regulates Schwann cell
behavior will be challenging. For example,
the prodifferentiation factor, Egr2, and
the dedifferentiation factor, c-Jun, are
both activated by ERK/MAPK signaling
(Newbern et al., 2011; Syed et al., 2010).
Aside from the control of transcriptional
mediators, defining how ERK/MAPK
might impact epigenetic modifications
and the expression of microRNAs impor-
tant for myelination will be vital as well
(reviewed in Pereira et al., 2012).
Schwann cell dedifferentiation is critical
to the injury response. However, inappro-
priate activation of this process may also
contribute to pathological states, such
as peripheral nerve tumors. Mutations in
neurofibromin-1, a Ras-GAP, typically
lead to overactive ERK/MAPK signaling
and neurofibromatosis type 1 (NF1). A
typical feature of NF1 is the formation of626 Neuron 73, February 23, 2012 ª2012 Elsperipheral nerve tumors that appear to
be composed of progenitor-like Schwann
cells. The findings of Napoli et al. provide
further support for the idea that height-
ened ERK/MAPK signaling maintains
these precursors in a relatively undifferen-
tiated state and increases susceptibility
to oncogenesis (Parrinello et al., 2008).
Inhibition of ERK/MAPK signaling or
inhibition of factors derived from dedif-
ferentiated Schwann cells may provide
a relevant therapeutic strategy for pre-
venting protumorigenic changes in NF1.
In contrast to the robust peripheral
nerve regeneration that occurs in rodents,
the distances involved after nerve injury in
humans often lead to limited recovery.
This regeneration failure may be due, in
part, to extensive Schwann cell atrophy
that has been observed in experimental
animals when axon regeneration is de-
layed. Indeed, regenerating axons are
unable to innervate distal nerve stumps
that have been denervated for over a
month (Gordon et al., 2011). Thus, it is
intriguing to consider whether reversibly
activating ERK/MAPK in Schwann cells
distal to the site of injury via adminis-
tration of growth factors or other mecha-
nisms would prolong the maintenance of
an environment amenable to regrowth.
Indeed, the method described here for
inducing ERK/MAPK activation in vivo
provides a tool for tackling this interesting
problem.REFERENCES
Arthur-Farraj, P., Wanek, K., Hantke, J., Davis,
C.M., Jayakar, A., Parkinson, D.B., Mirsky, R.,
and Jessen, K.R. (2011). Glia 59, 720–733.evier Inc.Benowitz, L.I., and Popovich, P.G. (2011). Curr.
Opin. Neurol. 24, 577–583.
Chen, Z.L., Yu, W.M., and Strickland, S. (2007).
Annu. Rev. Neurosci. 30, 209–233.
Gordon, T., Tyreman, N., and Raji, M.A. (2011).
J. Neurosci. 31, 5325–5334.
Grossmann, K.S., Wende, H., Paul, F.E., Cheret,
C., Garratt, A.N., Zurborg, S., Feinberg, K., Besser,
D., Schulz, H., Peles, E., et al. (2009). Proc. Natl.
Acad. Sci. USA 106, 16704–16709.
Harrisingh, M.C., Perez-Nadales, E., Parkinson,
D.B., Malcolm, D.S., Mudge, A.W., and Lloyd,
A.C. (2004). EMBO J. 23, 3061–3071.
Monje, P.V., Soto, J., Bacallao, K., andWood, P.M.
(2010). J. Biol. Chem. 285, 31024–31036.
Napoli, I., Noon, L.A., Ribeiro, S., Kerai, A.P.,
Parrinello, S., Rosenberg, L.H., Collins, M.J., Harri-
singh, M.C., White, I.J., Woodhoo, A., and Lloyd,
A.C. (2012). Neuron 73, this issue, 729–742.
Newbern, J.M., Li, X., Shoemaker, S.E., Zhou, J.,
Zhong, J.,Wu, Y., Bonder, D., Hollenback, S., Cop-
pola, G., Geschwind, D.H., et al. (2011). Neuron 69,
91–105.
Parkinson, D.B., Bhaskaran, A., Arthur-Farraj, P.,
Noon, L.A., Woodhoo, A., Lloyd, A.C., Feltri, M.L.,
Wrabetz, L., Behrens, A., Mirsky, R., and Jessen,
K.R. (2008). J. Cell Biol. 181, 625–637.
Parrinello, S., Noon, L.A., Harrisingh, M.C., Digby,
P.W., Rosenberg, L.H., Cremona, C.A., Echave,
P., Flanagan, A.M., Parada, L.F., and Lloyd, A.C.
(2008). Genes Dev. 22, 3335–3348.
Pereira, J.A., Lebrun-Julien, F., and Suter, U.
(2012). Trends Neurosci. 35, 123–134. Published
online December 21, 2011.
Sheu, J.Y., Kulhanek, D.J., and Eckenstein, F.P.
(2000). Exp. Neurol. 166, 392–402.
Syed, N., Reddy, K., Yang, D.P., Taveggia, C.,
Salzer, J.L., Maurel, P., and Kim, H.A. (2010).
J. Neurosci. 30, 6122–6131.
Woodhoo, A., Alonso, M.B., Droggiti, A., Turmaine,
M., D’Antonio, M., Parkinson, D.B., Wilton, D.K.,
Al-Shawi, R., Simons, P., Shen, J., et al. (2009).
Nat. Neurosci. 12, 839–847.
